BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16361046)

  • 1. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions.
    Kaplan GG; Bates D; McDonald D; Panaccione R; Romagnuolo J
    Clin Gastroenterol Hepatol; 2005 Dec; 3(12):1207-14. PubMed ID: 16361046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: a multicentre comparative study.
    Andrews CN; Levy A; Fishman M; Hahn M; Atkinson K; Kwan P; Enns R
    Can J Gastroenterol; 2005 Nov; 19(11):667-71. PubMed ID: 16292361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Description of prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton pump inhibitors: a multicentre evaluation.
    Enns R; Andrews CN; Fishman M; Hahn M; Atkinson K; Kwan P; Levy A
    Can J Gastroenterol; 2004 Sep; 18(9):567-71. PubMed ID: 15457296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a U.S. multicenter randomized, double-blind study.
    Jensen DM; Pace SC; Soffer E; Comer GM;
    Am J Gastroenterol; 2006 Sep; 101(9):1991-9; quiz 2170. PubMed ID: 16968504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage?
    Guda NM; Noonan M; Kreiner MJ; Partington S; Vakil N
    Am J Gastroenterol; 2004 Jul; 99(7):1233-7. PubMed ID: 15233659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical importance of proton pump inhibitor pharmacokinetics.
    Yacyshyn BR; Thomson AB
    Digestion; 2002; 66(2):67-78. PubMed ID: 12428065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less acid + less bleeding = better outcomes and more money!
    Enns R
    Can J Gastroenterol; 2004 Dec; 18(12):747-8; discussion 748. PubMed ID: 15605140
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous pantoprazole utilization in a level 1 trauma center.
    Edelman DA; Patel KR; Tyburski JG; Zimmerman LG
    Surg Endosc; 2008 Apr; 22(4):967-73. PubMed ID: 17710489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous proton pump inhibitor therapy: a rationale for use.
    Armstrong D
    Rev Gastroenterol Disord; 2005; 5 Suppl 2():S18-30. PubMed ID: 16369224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers.
    Hsu PI; Lo GH; Lo CC; Lin CK; Chan HH; Wu CJ; Shie CB; Tsai PM; Wu DC; Wang WM; Lai KH
    World J Gastroenterol; 2004 Dec; 10(24):3666-9. PubMed ID: 15534928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antisecretor treatment of digestive hemorrhage associated to peptic ulcer: an approximation to the available evidence].
    Bustamante Baléna M; Ponce García J
    Rev Clin Esp; 2004 Mar; 204(3):161-8. PubMed ID: 15025985
    [No Abstract]   [Full Text] [Related]  

  • 12. The novel use of an intravenous proton pump inhibitor in a patient with short bowel syndrome.
    Tang SJ; Nieto JM; Jensen DM; Ohning GV; Pisegna JR
    J Clin Gastroenterol; 2002 Jan; 34(1):62-3. PubMed ID: 11743248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)].
    Leitner A; Zöllner P
    Wien Med Wochenschr; 2002; 152(21-22):568-73. PubMed ID: 12506681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial.
    Zargar SA; Javid G; Khan BA; Yattoo GN; Shah AH; Gulzar GM; Sodhi JS; Mujeeb SA; Khan MA; Shah NA; Shafi HM
    J Gastroenterol Hepatol; 2006 Apr; 21(4):716-21. PubMed ID: 16677158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
    Regula J; Butruk E; Dekkers CP; de Boer SY; Raps D; Simon L; Terjung A; Thomas KB; Lühmann R; Fischer R
    Am J Gastroenterol; 2006 Aug; 101(8):1747-55. PubMed ID: 16817839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice--a prospective study of the extent of the problem and predictive factors.
    Craig DG; Thimappa R; Anand V; Sebastian S
    QJM; 2010 May; 103(5):327-35. PubMed ID: 20211846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitors: a study of GPs' prescribing.
    Jones MI; Greenfield SM; Jowett S; Bradley CP; Seal R
    Fam Pract; 2001 Jun; 18(3):333-8. PubMed ID: 11356744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
    Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
    Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of proton pump inhibitors in the treatment of gastrointestinal hemorrhage.
    Martin RA
    Conn Med; 2004 Aug; 68(7):435-8. PubMed ID: 15384242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.